EMPLOYMENT AGREEMENTEmployment Agreement • October 24th, 2018 • Melinta Therapeutics, Inc. /New/ • Pharmaceutical preparations • Delaware
This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into this this 22nd day of October 2018, by and between Melinta Therapeutics, Inc., a Delaware corporation (the “Company”), and John Johnson (“Executive”).
October 23, 2018 Mr. Daniel Mark Wechsler Address on file with the Company Dear Dan, Reference is hereby made to the employment agreement by and between you and Melinta Therapeutics, Inc. (together with its subsidiaries, “Melinta”), dated October 30,...Melinta Therapeutics, Inc. /New/ • October 24th, 2018 • Pharmaceutical preparations
In connection with the termination of your employment, effective as of October 18, 2018 (the “Separation Date”), in addition to any other payments or benefits due to you under the Employment Agreement, twenty-five percent (25%) of the restricted stock units covered by the RSU Grant (or 45,915 restricted stock units) will vest on December 31, 2018 (the “Vesting Date”), subject to your executing, delivering and not revoking the Release of Claims as required pursuant to Section 8(g) of the Employment Agreement and your continued compliance with the Restrictive Covenant Agreement through the Vesting Date. For the avoidance of doubt, the remaining restricted stock units covered by the RSU Grant and all other unvested equity awards granted to you by Melinta which were outstanding on the Separation Date shall remain outstanding following the Separation Date and subject to vesting (if a Change in Control (as defined in the Employment Agreement) occurs at any time within three months following
